These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1426312)

  • 1. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
    Anttila L; Koskinen P; Kaihola HL; Erkkola R; Irjala K; Ruutiainen K
    Fertil Steril; 1992 Oct; 58(4):697-702. PubMed ID: 1426312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease.
    Anttila L; Ding YQ; Ruutiainen K; Erkkola R; Irjala K; Huhtaniemi I
    Fertil Steril; 1991 Jun; 55(6):1057-61. PubMed ID: 1903726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease.
    Anttila L; Koskinen P; Erkkola R; Irjala K; Ruutiainen K
    Acta Obstet Gynecol Scand; 1994 Sep; 73(8):634-6. PubMed ID: 7941988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A; Rosenn B; Palti Z; Ebstein B; Har-Nir R; Ron M
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome.
    Koskinen P; Penttilä TA; Anttila L; Erkkola R; Irjala K
    Fertil Steril; 1996 Mar; 65(3):517-22. PubMed ID: 8774279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
    Berga SL; Yen SS
    Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
    Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum total renin is elevated in women with polycystic ovarian syndrome.
    Jaatinen TA; Matinlauri I; Anttila L; Koskinen P; Erkkola R; Irjala K
    Fertil Steril; 1995 May; 63(5):1000-4. PubMed ID: 7720907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function.
    Okon MA; Laird SM; Tuckerman EM; Li TC
    Fertil Steril; 1998 Apr; 69(4):682-90. PubMed ID: 9548158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity, serum steroid levels, and pulsatile gonadotropin secretion in polycystic ovarian disease.
    Laatikainen T; Tulenheimo A; Andersson B; Kärkkäinen J
    Eur J Obstet Gynecol Reprod Biol; 1983 Apr; 15(1):45-53. PubMed ID: 6224711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum free testosterone in polycystic ovary syndrome measured with a new reference method.
    Penttilä TA; Anttila L; Törmä A; Koskinen P; Erkkola R; Irjala K
    Fertil Steril; 1996 Jan; 65(1):55-60. PubMed ID: 8557155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex hormone profiles in oligomenorrheic adolescent girls and the effect of oral contraceptives.
    Siegberg R; Nilsson CG; Stenman UH; Widholm O
    Fertil Steril; 1984 Jun; 41(6):888-93. PubMed ID: 6233177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.
    Seyam E; Hefzy E
    Gynecol Endocrinol; 2018 Jun; 34(6):481-488. PubMed ID: 29254383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen and androgen states in oligo-amenorrhoeic women with polycystic ovaries.
    Fox R; Corrigan E; Thomas PG; Hull MG
    Br J Obstet Gynaecol; 1991 Mar; 98(3):294-9. PubMed ID: 1827032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.